TISIDB

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Single-pass type I membrane protein
Domain	PF00040 Fibronectin type II domain PF08238 Sel1 repeat
Function	Plays a role in the endoplasmic reticulum quality control (ERQC) system also called ER-associated degradation (ERAD) involved in ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins (PubMed:16186509). Enhances SYVN1 stability. Plays a role in LPL maturation and secretion. Required for normal differentiation of the pancreas epithelium, and for normal exocrine function and survival of pancreatic cells. May play a role in Notch signaling.

> Gene Ontology [ TOP ]
Biological Process	GO:0006517 protein deglycosylation GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006641 triglyceride metabolic process GO:0007219 Notch signaling pathway GO:0009306 protein secretion GO:0010498 proteasomal protein catabolic process GO:0030433 ER-associated ubiquitin-dependent protein catabolic process GO:0030970 retrograde protein transport, ER to cytosol GO:0031647 regulation of protein stability GO:0032527 protein exit from endoplasmic reticulum GO:0034976 response to endoplasmic reticulum stress GO:0036503 ERAD pathway GO:0036507 protein demannosylation GO:0036508 protein alpha-1,2-demannosylation GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0046486 glycerolipid metabolic process GO:0050821 protein stabilization GO:1903513 endoplasmic reticulum to cytosol transport GO:1904380 endoplasmic reticulum mannose trimming
Molecular Function	-
Cellular Component	GO:0000151 ubiquitin ligase complex GO:0000153 cytoplasmic ubiquitin ligase complex GO:0000835 ER ubiquitin ligase complex GO:0000836 Hrd1p ubiquitin ligase complex GO:0000839 Hrd1p ubiquitin ligase ERAD-L complex GO:0036513 Derlin-1 retrotranslocation complex GO:0044322 endoplasmic reticulum quality control compartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04141 Protein processing in endoplasmic reticulum
Reactome	R-HSA-5619084: ABC transporter disorders R-HSA-382556: ABC-family proteins mediated transport R-HSA-446203: Asparagine N-linked glycosylation R-HSA-901042: Calnexin/calreticulin cycle R-HSA-5678895: Defective CFTR causes cystic fibrosis R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-5619115: Disorders of transmembrane transporters R-HSA-901032: ER Quality Control Compartment (ERQC) R-HSA-5358346: Hedgehog ligand biogenesis R-HSA-5387390: Hh mutants abrogate ligand secretion R-HSA-5362768: Hh mutants that don't undergo autocatalytic processing are degraded by ERAD R-HSA-392499: Metabolism of proteins R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle R-HSA-597592: Post-translational protein modification R-HSA-1912422: Pre-NOTCH Expression and Processing R-HSA-1912420: Pre-NOTCH Processing in Golgi R-HSA-162582: Signal Transduction R-HSA-5358351: Signaling by Hedgehog R-HSA-157118: Signaling by NOTCH R-HSA-382551: Transmembrane transport of small molecules

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04141 Protein processing in endoplasmic reticulum

Reactome

R-HSA-5619084: ABC transporter disorders
R-HSA-382556: ABC-family proteins mediated transport
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-901042: Calnexin/calreticulin cycle
R-HSA-5678895: Defective CFTR causes cystic fibrosis
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-5619115: Disorders of transmembrane transporters
R-HSA-901032: ER Quality Control Compartment (ERQC)
R-HSA-5358346: Hedgehog ligand biogenesis
R-HSA-5387390: Hh mutants abrogate ligand secretion
R-HSA-5362768: Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-597592: Post-translational protein modification
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912420: Pre-NOTCH Processing in Golgi
R-HSA-162582: Signal Transduction
R-HSA-5358351: Signaling by Hedgehog
R-HSA-157118: Signaling by NOTCH
R-HSA-382551: Transmembrane transport of small molecules

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SEL1L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SEL1L in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 1.48; FDR: 0.000424	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SEL1L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.215	0.533
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.5	0.804
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.011	0.994
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.079	0.762
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.048	0.982
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.24	0.929
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.192	0.701
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.361	0.864
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.019	0.993
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.192	0.898
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.051	0.623
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.014	0.83

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SEL1L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SEL1L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SEL1L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SEL1L. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SEL1L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SEL1L expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SEL1L and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SEL1L
Name	sel-1 suppressor of lin-12-like (C. elegans)
Aliases	SEL1L1; sel-1 suppressor of lin-12-like 1 (C. elegans); sel-1 (suppressor of lin-12, C.elegans)-like; PRO106 ......
Chromosomal Location	14q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SEL1L collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SEL1L